Besides VEGF-A, whose neutralization was conducted as a proof-of-concept approach for the discovery of orthogonal combination therapy, we noted additional candidate compensatory pathways enriched in the Treg cell-poor or cell-depleted TME including the CCR2–CCL2 axis, inhibitors of which are currently tested as monotherapies or combination therapies of human cancers. This evidence concerns the gene VEGFA and cancer.